Navigation Links
Pharmaceutical Industry Service Company Awarded The UK's Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
Date:4/20/2012

LONDON, April 21, 2012 /PRNewswire/ --

Medaxial, the healthcare value communication specialist, today announces that it has won a Queen's Award for Enterprise in recognition of its international trade achievements.

The Queen's Awards for Enterprise are the UK's most prestigious business accolade, bestowed by Her Majesty Queen Elizabeth II on a select number of companies who have achieved outstanding results in international trade, innovation or sustainable development.  The awards are announced each year on April 21, The Queen's birthday.

Medaxial provides value communication solutions to many of the best-known names in the pharmaceutical, medical devices and diagnostics industries, and has been particularly successful in developing a client base in Europe and the USA.  The company's portfolio of services includes landscape and competitor assessment, clinical trial optimisation advice, pricing research, revenue forecasting, value message development and testing, strategic market access consultancy, health economic modelling, value dossier development, value communication toolkits and a wide range of tactical sales tools.  

Reacting to the news, one of the founding directors of Medaxial, John Fanshawe, said, "We have always believed that Medaxial's unique value communication perspective helps our clients to prosper in what are very difficult market conditions.  With continued pressure on healthcare budgets and the ever-increasing cost of bringing products to market, most pharmaceutical, biotechnology and medical devices companies now recognise the critical importance of successfully communicating the value of their products to the stakeholders who are expected to pay for them.  We have remained faithful to our belief in the central importance of value communication, and have built a reputation within the global healthcare industry for combining a rigorous approach to science and health economics with world-class communication expertise."

Paul Mcloughlin, also a founding director, added, "As a British company competing against some major overseas players, we operate in a tough and unforgiving marketplace, so we are absolutely delighted to receive this recognition.  Our growth over recent years is a testament to our understanding of the healthcare industry and the issues it faces, our insight into the decision-making processes in global healthcare systems, and the innovative value communication solutions that we provide."

About Medaxial

Medaxial is a specialist value communication consultancy with more than 15 years' experience of serving the global healthcare industry.  The services the company offers are based on two core beliefs: First, that no activity is more important to innovative healthcare companies than the communication of product value; and second, that value communication is inextricably linked to pricing, reimbursement, stakeholder research, health economic research and clinical evidence generation.

Medaxial is the only consultancy specialising in value communication that offers health economic, pricing and market access services. The company's value communication perspective ensures that all activities are focused on the central task of communicating product value in order to optimise commercial success.

The result is a highly-focused portfolio of services that helps clients demonstrate the value of innovative medicines, medical devices and diagnostic technologies, based on robust scientific evidence and high-quality market research.  

Medaxial is headquartered in London, England, and has an office in New York City serving the North American marketplace.  

About the Queen's Awards

Click this link for more information about The Queen's Awards



'/>"/>
SOURCE Medaxial
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)...  West Pharmaceutical Services, Inc. (NYSE: WST ... 2017 and updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, ... Net sales at constant currency (organic) grew by 3.9%. ... compared to $0.60 in the prior-year quarter. Second-quarter 2017 ...
(Date:7/26/2017)... Aesthetics, a leading medical aesthetic clinic in Singapore ... skin conditions from the inside. The natural process of ... skin becomes more transparent due to the thinning of the epidermis. Over ... the sun contributes to aging skin, causing age spots and other ... ...
(Date:7/26/2017)... 26, 2017 The Galien Foundation announced ... USA Award Nominees. Counted among the global ... recognizes outstanding biomedical and technology product achievement that improves the ... qualify, each candidate must be U.S. Food and Drug Administration ... demonstrate tremendous potential to impact human health. Sales data are ...
Breaking Medicine Technology:
(Date:7/27/2017)... Plano, TX (PRWEB) , ... July 27, 2017 ... ... technology and outsourced services, announces the internal promotion of Elrene Clinkscales to Vice ... Operations – Claims & Remittance Management, reporting to Derek Morkel, chief executive officer ...
(Date:7/27/2017)... ... 2017 , ... Team Novo Nordisk, the world’s first all-diabetes professional cycling team, ... a stagiaire for the remainder of the 2017 season. One of our best development ... Tour of Utah. , “Every season we are excited to move an athlete from ...
(Date:7/26/2017)... ... July 26, 2017 , ... Written By: Ashley D. Beall, ... in drug therapy for patients living with relapsing and primary multiple sclerosis that ... cell targeted therapy that has been proven to significantly reduce signs of disease ...
(Date:7/26/2017)... ... July 26, 2017 , ... “We are dentists and we thought there ... Jose, Calif., “so we invented the MAGNETIC/ LOCK BRACKETS.” , The patent-pending MAGNETIC/ LOCK ... In doing so, it offers an effective alternative to traditional braces. As a result, ...
(Date:7/26/2017)... ... July 26, 2017 , ... “We are thrilled to be ... for patients to schedule an appointment online in real time,” said Keith English, LocalMed ... Smiles provider directory will bring more Six Month Smiles patients to their providers.” , ...
Breaking Medicine News(10 mins):